ArticlePLOS digital health2026
Dynamically predicting renal failure after development of diabetes across biobanks.
Article in PLOS digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
End-stage renal disease (ESRD) remains a major complication of diabetes, yet existing static risk scores may lose accuracy as patient profiles evolve and competing mortality risks change over time. We developed and externally validated a landmark-based ESRD Dynamic Risk Score (ESRD-DRS) that updates individual risk estimates at 1, 5, and 10 years after diabetes diagnosis using routinely collected EHR data. We assembled a retrospective cohort of 708,435 U.S. Veterans with newly diagnosed diabetes in the Veterans Health Administration (VHA). At 1, 5, and 10 years after diabetes diagnosis (LM1, LM5, and LM10), we fit penalized Fine-Gray subdistribution hazard models, drawing from more than 400 demographic, medication, comorbidity, and laboratory variables. Models were evaluated over 1-, 5-, and 10-year horizons for discrimination (area under the time-dependent receiver operating characteristic curve [AUROC]) and calibration (Brier score), and compared with the established RECODe and 4-variable KFRE risk equations. External validation was performed in an independent All of Us (AoU) cohort (n = 13,223). In the VHA cohort (median follow-up 7.6 years), 8,955 patients (1.26%) developed ESRD, and 136,666 (19.3%) died without ESRD. At LM1, ESRD-DRS achieved AUROCs of 0.93, 0.90, and 0.85 for 1-, 5-, and 10-year risk, respectively, and Brier scores ranging from 0.00098 to 0.0162. In the AoU cohort, corresponding AUROCs were 0.94, 0.91, and 0.86, with similar calibration performance. RECODe and KFRE yielded lower discrimination and poorer calibration. Top risk predictors, including estimated glomerular filtration rate, albuminuria, systolic blood pressure, and age, were consistent across landmarks and cohorts. ESRD-DRS, a scalable landmark approach that accounts for competing mortality and evolving patient profiles, outperformed existing static equations. Embedding ESRD-DRS into EHR workflows may support more timely, individualized ESRD risk assessment in patients with diabetes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.